Please assess the completion status of the following clinical trial:

Trial Title: Long-term Topical Cyclosporine for Atopic Keratoconjunctivitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has known diagnosis of atopic keratoconjunctivitis~* Patient has been on cyclosporine 0.05% eye drops for control of atopic keratoconjunctivitis~* Patient has been followed up for at least for 1 year~* Patient is able to give informed consent~* Patient is able to tolerate a full ophthalmic exam~Exclusion Criteria:~* Patient has any other diagnosis (i.c. vernal keratoconjunctivitis, giant papillary conjunctivitis) that may alter the clinical appearance or behavior of their ocular surface)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclosporine 0.05% ophthalmic (Type: EXPERIMENTAL): cyclosporine 0.05% ophthalmic eye drops will be used starting with 1 drop in both eyes 6 times daily for first month, followed by 1 drop in both eyes 4 times daily for the following month, then will be adjusted by clinician as needed for appropriate disease control

Based on this trial design, predict the completion outcome and termination type (if applicable).